Here's an interesting experimental drug to watch if your cancer is HER2 positive or HER2 low (IHC 2+ or IHC 1+). It has been written up in my book, "The Insider's Guide to Metastatic Breast Cancer" which is available in paperback and eBook formats as well as in a complimentary .pdf. If interested, please visit insidersguidembc.com
The recent Phase 2 DESTINY BreastO1 clinical trial studied the experimental drug trastuzumab deruxtecan in 115 patients with unresectable and/or metastatic cancer who had previously received a median 7 lines of therapy including Herceptin and Kadcyla (as well as Perjeta in most cases). The patients in the study had either: HER2-positive breast cancer, HER2–low expressing breast cancer (considered HER2 negative), HER2-positive gastric cancer, or various other HER2-expressing solid tumors.
Data revealed that the overall response rate with trastuzumab deruxtecan was 59.5% and the disease control rate was an impressive 93.7%. The median duration of response was 20.7 months, the median progression-free survival was 22.1 months, and the median overall survival has not yet been reached. From: targetedonc.com/news/fam-tr... As of May 2019, there are three recruiting clinical trials of trastuzumab deruxtecan for MBC patients.
